B7H3 (CD276), a key immune checkpoint molecule that is overexpressed in tumors, plays a central role in cancer progression, making it a highly promising and specific therapeutic target. Here, we discovered that the cellular metabolite palmitic acid contributes to the development of an immunosuppr...
B7H3 (also known as CD276) is a co-stimulator checkpoint protein of the cell surface B7 superfamily. Recently, the function beyond immune regulation of B7H3 has been widely studied. However, the expression preference and the regulation mechanism underlying B7H3 in different subtypes of gliomas is ra...
B7-H3 has emerged as a promising target for cancer therapy due to its high expression in various types of cancer cells. It not only regulates the activity of immune cells but also modulates the signal transduction and metabolism of cancer cells. However, the specific interaction partners of B7-H3 st...
Immunoprecipitation coupled with mass spectrometry (IP/MS) was performed in HaCaT cells using an anti-B7-H3 antibody to identify B7-H3-interacting proteins. Raw mass spectrometry data are provided.
B7-H3, an immune checkpoint molecule, is overexpressed in various solid cancers, correlating with negative prognosis and poor clinical outcomes. However, its regulatory mechanisms in aggressive cancers and cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, ...
Fibroblast growth factor receptor substrate 2 (FRS2) and B7-H3/CD276 are both highly expressed in medulloblastoma (MB) patient samples. While FRS2 has been shown to drive an invasive tumor phenotype, the biological role of B7-H3/CD276 is still incompeletely understood. Here, we explored the interact...
The study entails the design, production and in vitro testing of a novel recombinant anti-B7-H3 affibody coupled with a small cytotoxic protein, with considerable potential in Acute Myeloid Leukemia (AML) immunotherapy. The protein construct was expressed in E. coli. After affinity purification and ...
